Clinical results from the use of Episealer® to be presented at the annual meeting of the Swedish Orthopaedic Association
Episurf Medical (NASDAQ: EPIS B) today announces that the scientific abstract “Clinical results of an individualized mini-metal implant for focal cartilage lesions in the knee” by Ass. Prof. Karl Eriksson has been accepted for presentation at the annual congress of the Swedish Orthopaedic Association. The congress will take place in Karlstad, Sweden on August 27-31, 2018. The abstract focuses on patients treated with the Episealer® knee implant for focal cartilage lesions. The results will be presented by Ass. Prof. Karl Eriksson from the from Stockholm South General Hospital, Sweden.
“In the abstract it is concluded that the study shows excellent early clinical results in the treatment of focal symptomatic cartilage lesions. The results show high patient reported scores and a low early revision rate and this is exactly what we want to achieve. Our customers attest to the treatment gap and all proofs of successful treatment of this patient group are highly interesting” says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
Tags: